Fundsmith LLP
13F filer · CIK 0001569205Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$13.6BU.S. long equity reported on 13F
Positions4113 new · 6 closed
Net flow last quarter-$555MBuys minus sells
Top 10 positions weight52.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202641 positions | |||||
| $958M | 7.02% | 0.98% | -23.3% | Q1 2015 | |
| $917M | 6.72% | 0.76% | -4.8% | Q1 2013 | |
| $853M | 6.25% | 2.32% | -29.2% | Q1 2013 | |
| $693M | 5.08% | 0.11% | -34.9% | Q1 2013 | |
| $645M | 4.73% | 0.44% | New | Q2 2026 | |
| $639M | 4.69% | 0.10% | Not reported | Q1 2023 | |
| $634M | 4.64% | 0.01% | -40.0% | Q4 2021 | |
| $626M | 4.58% | 2.73% | -2.8% | Q3 2019 | |
| $598M | 4.38% | 0.18% | -2.9% | Q1 2013 | |
| $596M | 4.36% | 0.02% | -23.2% | Q1 2013 | |
| $593M | 4.34% | Not reported | -20.4% | Q2 2018 | |
| $583M | 4.27% | 0.65% | -32.5% | Q1 2013 | |
| $558M | 4.09% | 0.49% | -41.0% | Q3 2020 | |
| $548M | 4.02% | 0.00% | Not reported | Q4 2020 | |
| $537M | 3.93% | 1.29% | -30.4% | Q1 2015 | |
| $536M | 3.93% | 0.20% | -31.4% | Q1 2024 | |
| $527M | 3.86% | 0.19% | -43.0% | Q1 2013 | |
| $499M | 3.66% | 0.17% | New | Q2 2026 | |
| $481M | 3.53% | 0.15% | New | Q2 2026 | |
| $359M | 2.63% | 0.21% | New | Q2 2026 | |
| $344M | 2.52% | 0.21% | New | Q2 2026 | |
| $340M | 2.49% | 2.09% | New | Q2 2026 | |
| $145M | 1.06% | 0.50% | New | Q2 2026 | |
| $88.9M | 0.65% | 0.20% | New | Q2 2026 | |
| $30M | 0.22% | 0.07% | -17.3% | Q4 2018 | |
| $27.7M | 0.20% | 0.19% | -16.4% | Q4 2024 | |
| $27.4M | 0.20% | 0.20% | -6.8% | Q4 2025 | |
| $25.9M | 0.19% | 0.60% | +22.6% | Q1 2026 | |
| $25.9M | 0.19% | 0.22% | +5.5% | Q4 2019 | |
| $25.9M | 0.19% | 0.13% | Not reported | Q1 2021 | |
| $24.1M | 0.18% | 0.30% | +43.1% | Q2 2025 | |
| $23.1M | 0.17% | 1.70% | +58.2% | Q2 2025 | |
| $21.4M | 0.16% | 0.08% | New | Q2 2026 | |
| $18.8M | 0.14% | 2.23% | Not reported | Q4 2018 | |
| $17.1M | 0.13% | 0.23% | New | Q2 2026 | |
| $15M | 0.11% | 0.02% | New | Q2 2026 | |
| $14M | 0.10% | 0.01% | -54.1% | Q2 2025 | |
| $14M | 0.10% | 0.06% | -50.9% | Q4 2018 | |
| $13.8M | 0.10% | 0.73% | Not reported | Q4 2025 | |
| $13.5M | 0.10% | 0.36% | -5.6% | Q4 2024 | |
| $12.7M | 0.09% | 0.23% | -54.1% | Q4 2018 | |
| Q1 2026Reported May 15, 202634 positions | |||||
| $1.1B | 8.59% | 1.27% | -15.3% | Q1 2015 | |
| $1.01B | 7.84% | 0.80% | -17.0% | Q1 2013 | |
| $957M | 7.46% | 3.27% | -9.7% | Q1 2013 | |
| $938M | 7.31% | 0.17% | -12.2% | Q1 2013 | |
| $850M | 6.63% | 0.02% | -15.5% | Q4 2021 | |
| $845M | 6.59% | 0.33% | -16.5% | Q1 2013 | |
| $824M | 6.42% | 1.85% | -21.9% | Q1 2015 | |
| $783M | 6.11% | 0.96% | -7.7% | Q1 2013 | |
| $770M | 6.00% | 0.03% | 0.0% | Q1 2013 | |
| $756M | 5.89% | Not reported | -3.1% | Q2 2018 | |
| $717M | 5.59% | 2.81% | -2.1% | Q1 2022 | |
| $620M | 4.83% | 2.81% | -1.3% | Q3 2019 | |
| $607M | 4.73% | 0.18% | -1.1% | Q1 2013 | |
| $509M | 3.97% | 0.29% | 0.0% | Q1 2024 | |
| $503M | 3.92% | 0.84% | -5.5% | Q3 2020 | |
| $458M | 3.57% | 0.92% | -0.6% | Q4 2020 | |
| $211M | 1.64% | 0.70% | -12.2% | Q3 2022 | |
| $34.9M | 0.27% | 0.09% | -61.1% | Q4 2018 | |
| $33.1M | 0.26% | 0.13% | -58.1% | Q1 2021 | |
| $30.1M | 0.23% | 0.22% | -24.1% | Q4 2024 | |
| $28.2M | 0.22% | 0.12% | -58.1% | Q4 2018 | |
| $26.7M | 0.21% | 0.47% | -58.1% | Q4 2018 | |
| $26.7M | 0.21% | 0.21% | -58.1% | Q4 2019 | |
| $22.9M | 0.18% | 0.02% | -77.8% | Q2 2025 | |
| $21.9M | 0.17% | 0.22% | -58.1% | Q4 2025 | |
| $21.7M | 0.17% | 0.49% | New | Q1 2026 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $20.9M | 0.16% | 0.69% | -74.9% | Q1 2025 |
| $19.9M | 0.15% | 0.64% | -65.1% | Q2 2020 | |
| $16.1M | 0.13% | 0.38% | -58.1% | Q4 2024 | |
| $16.1M | 0.13% | 0.20% | -58.1% | Q2 2025 | |
| $15.1M | 0.12% | 1.07% | -78.5% | Q2 2025 | |
| $14.9M | 0.12% | 0.71% | -21.5% | Q4 2025 | |
| $13.1M | 0.10% | 2.28% | -58.1% | Q4 2018 | |
| $9.41M | 0.07% | 0.00% | -64.3% | Q1 2021 | |
| Q4 2025Reported Feb 17, 202637 positions | |||||
| $1.35B | 7.90% | 5.97% | -10.1% | Q1 2013 | |
| $1.3B | 7.57% | 0.96% | -19.7% | Q1 2013 | |
| $1.27B | 7.42% | 2.35% | -28.1% | Q1 2015 | |
| $1.24B | 7.24% | 0.19% | -8.3% | Q1 2013 | |
| $1.23B | 7.21% | 1.50% | -5.9% | Q1 2015 | |
| $1.1B | 6.40% | 0.03% | -44.4% | Q4 2021 | |
| $1.07B | 6.28% | 1.04% | -3.1% | Q1 2013 | |
| $1.01B | 5.88% | 0.03% | -19.5% | Q1 2013 | |
| $982M | 5.74% | 0.39% | -14.8% | Q1 2013 | |
| $900M | 5.26% | Not reported | -12.5% | Q2 2018 | |
| $809M | 4.73% | 2.62% | -1.7% | Q1 2022 | |
| $609M | 3.56% | 0.18% | -7.2% | Q1 2013 | |
| $564M | 3.30% | 2.80% | -1.0% | Q3 2019 | |
| $517M | 3.02% | 0.88% | -22.6% | Q3 2020 | |
| $491M | 2.87% | 0.92% | +7.9% | Q4 2020 | |
| $455M | 2.66% | 0.29% | -3.6% | Q1 2024 | |
| $414M | 2.42% | 0.22% | +3.5% | Q2 2017 | |
| $368M | 2.15% | 0.34% | -5.9% | Q1 2020 | |
| $272M | 1.59% | 0.80% | -46.5% | Q3 2022 | |
| $95.6M | 0.56% | 0.23% | Not reported | Q4 2018 | |
| $88.7M | 0.52% | 0.31% | Not reported | Q1 2021 | |
| $86.1M | 0.50% | 1.81% | -25.6% | Q2 2020 | |
| $83.4M | 0.49% | 0.96% | Not reported | Q4 2018 | |
| $83.3M | 0.49% | Not reported | +46.4% | Q3 2023 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $78.5M | 0.46% | 2.75% | Not reported | Q1 2025 |
| $74.2M | 0.43% | 4.99% | Not reported | Q2 2025 | |
| $73.1M | 0.43% | 0.89% | +21.7% | Q4 2024 | |
| $71.2M | 0.42% | 0.51% | New | Q4 2025 | |
| $66.6M | 0.39% | 0.11% | -30.5% | Q2 2025 | |
| $65.8M | 0.38% | 0.29% | Not reported | Q4 2018 | |
| $61.9M | 0.36% | 0.51% | Not reported | Q4 2019 | |
| $50M | 0.29% | 0.48% | Not reported | Q2 2025 | |
| $47.5M | 0.28% | 0.35% | -35.7% | Q1 2023 | |
| $46.4M | 0.27% | 0.29% | -35.3% | Q4 2024 | |
| $38.3M | 0.22% | 0.88% | New | Q4 2025 | |
| $29.2M | 0.17% | 5.44% | Not reported | Q4 2018 | |
| $27.6M | 0.16% | 0.01% | -5.5% | Q1 2021 | |
| Q3 2025Reported Nov 14, 202535 positions | |||||
| $1.7B | 8.57% | 1.20% | -1.8% | Q1 2013 | |
| $1.67B | 8.43% | 3.26% | -1.1% | Q1 2015 | |
| $1.53B | 7.72% | 0.05% | -7.6% | Q4 2021 | |
| $1.34B | 6.76% | 0.03% | -47.7% | Q1 2013 | |
| $1.32B | 6.65% | 0.21% | 0.0% | Q1 2013 | |
| $1.27B | 6.39% | 1.06% | -1.2% | Q1 2013 | |
| $1.19B | 5.99% | 6.65% | +9.6% | Q1 2013 | |
| $1.17B | 5.89% | 0.46% | -20.8% | Q1 2013 | |
| $1.14B | 5.78% | Not reported | -56.3% | Q2 2018 | |
| $1.1B | 5.56% | 1.56% | -0.2% | Q1 2015 | |
| $725M | 3.66% | 2.89% | +0.1% | Q1 2022 | |
| $708M | 3.58% | 1.13% | 0.0% | Q3 2020 | |
| $703M | 3.55% | 0.20% | +0.1% | Q1 2013 | |
| $595M | 3.01% | 2.79% | -0.4% | Q3 2019 | |
| $532M | 2.69% | 1.48% | Not reported | Q3 2022 | |
| $529M | 2.67% | 0.82% | +25.3% | Q4 2020 | |
| $500M | 2.53% | 0.30% | +0.1% | Q1 2024 | |
| $427M | 2.16% | 0.36% | Not reported | Q1 2020 | |
| $413M | 2.09% | 0.22% | +64.0% | Q2 2017 | |
| $115M | 0.58% | 2.43% | +21.2% | Q2 2020 | |
| $109M | 0.55% | 0.95% | +26.6% | Q4 2018 | |
| $99.2M | 0.50% | 0.72% | Not reported | Q4 2024 | |
| $94.5M | 0.48% | 0.22% | Not reported | Q4 2018 | |
| $89.2M | 0.45% | 0.15% | -18.4% | Q2 2025 | |
| $88.3M | 0.45% | Not reported | Not reported | Q3 2023 | |
| $86.9M | 0.44% | 0.31% | Not reported | Q1 2021 | |
| $76.5M | 0.39% | 0.54% | Not reported | Q1 2023 | |
| $76.4M | 0.39% | 4.99% | +86.4% | Q2 2025 | |
| $75.7M | 0.38% | 0.29% | Not reported | Q4 2018 | |
| $75.6M | 0.38% | 0.50% | Not reported | Q4 2019 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $66.3M | 0.33% | 2.73% | +24.2% | Q1 2025 |
| $65.6M | 0.33% | 0.45% | Not reported | Q4 2024 | |
| $59.1M | 0.30% | 0.48% | Not reported | Q2 2025 | |
| $39.3M | 0.20% | 5.44% | Not reported | Q4 2018 | |
| $34.4M | 0.17% | 0.01% | +1.8% | Q1 2021 | |
Premium opens every quarter this fund has filed